BSGM News
ViralClear adds St. David’s HealthCare in Austin, Texas, to its Planned Phase II trial for its Broad-Spectrum Oral Anti-Viral Candidate for COVID-19
June 5, 2020
BSGM News
ViralClear Publishes Comparative In Vitro Data on Merimepodib and Remdesivir Activity Against the COVID-19 Novel Coronavirus in F1000 Research
April 23, 2020
BSGM News
Positive Data Generated by Biosig Subsidiary ViralClear on Covid-19 Coronavirus Published in bioRxiv
April 14, 2020
BSGM News
Featured News
BioSig to Host Telebriefing on Development Updates Regarding Vicromax(tm), a Novel Broad-Spectrum Anti-Viral Candidate That May Treat COVID-19
April 3, 2020
BSGM News
Jerome Zeldis, M.D., Ph.D, Appointed as Executive Chair of ViralClear Pharmaceuticals, Inc.
March 31, 2020
BSGM News
BioSig subsidiary NeuroClear acquires license for a broad-spectrum anti-viral agent that may treat COVID-19. Laboratory results demonstrate high level of activity against COVID-19 in cell culture
March 25, 2020
BSGM News
BioSig Completes 100th Patient Case with PURE EP(tm) System
February 19, 2020
BSGM News
BioSig Technologies Signs a New Licensing Agreement with Mayo Clinic
September 12, 2019
BSGM News
Dr. Jerome Zeldis, M.D., Ph.D, Former Chief Medical Officer of Celgene, to Join BioSig Board of Directors
May 20, 2019
BSGM News
BioSig Technologies Completes Patient Cases at Indiana University
May 6, 2019
1
2
Sign Up & Get FREE News Alerts From FNM Today!
Sign Up
